These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12416899)

  • 1. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.
    Blower PR
    Cancer J; 2002; 8(5):405-14. PubMed ID: 12416899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
    Sanwald P; David M; Dow J
    Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
    Balfour JA; Goa KL
    Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists.
    Tateishi T; Nakura H; Watanabe M; Tanaka M; Kumai T; Kobayashi S
    Cancer Lett; 1996 Nov; 108(1):1-5. PubMed ID: 8950202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels.
    Kuryshev YA; Brown AM; Wang L; Benedict CR; Rampe D
    J Pharmacol Exp Ther; 2000 Nov; 295(2):614-20. PubMed ID: 11046096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.
    Bloomer JC; Baldwin SJ; Smith GJ; Ayrton AD; Clarke SE; Chenery RJ
    Br J Clin Pharmacol; 1994 Dec; 38(6):557-66. PubMed ID: 7888294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
    Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
    Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
    Gan TJ
    CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
    Seynaeve C; Verweij J; de Mulder PH
    Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting.
    Board T; Board R
    AORN J; 2006 Jan; 83(1):209-16, 219-20. PubMed ID: 16528908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport.
    Behnam-Motlagh P; Sandström PE; Henriksson R; Grankvist K
    Pharmacol Toxicol; 2001 May; 88(5):244-9. PubMed ID: 11393584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.